CIM
BBIO icon

Contravisory Investment Management’s BridgeBio Pharma BBIO Stock Holding History

Contravisory Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4K Hold
288
– – ﹤0.01% 299
2026
Q1 		$21.4K Sell
288
-10
-3% -$725 ﹤0.01% 291
2025
Q4 		$22.8K Hold
298
– – ﹤0.01% 293
2025
Q3 		$15.5K Buy
+298
New +$14.5K ﹤0.01% 321

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Contravisory Investment Management's BBIO Position: Q2 2026 in Review

Contravisory Investment Management held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 288 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #299.

Contravisory Investment Management first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $22.8K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Contravisory Investment Management held 288 shares of BridgeBio Pharma worth $21.4K as of Q2 2026.
  • Contravisory Investment Management left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Contravisory Investment Management's portfolio in Q2 2026, its #299 holding.
  • Contravisory Investment Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • Contravisory Investment Management's BridgeBio Pharma position peaked at $22.8K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.